Compare DEO & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DEO | NTRA |
|---|---|---|
| Founded | 1886 | 2003 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6B | 45.3B |
| IPO Year | 2001 | 2015 |
| Metric | DEO | NTRA |
|---|---|---|
| Price | $93.67 | $338.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | $109.00 | ★ $259.07 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 02-25-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.18% | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,939,000.00 |
| Revenue This Year | $2.65 | $18.08 |
| Revenue Next Year | N/A | $19.65 |
| P/E Ratio | $90.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $72.45 | $157.43 |
| 52 Week High | $113.05 | $337.12 |
| Indicator | DEO | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 60.45 | 72.33 |
| Support Level | $78.39 | $187.64 |
| Resistance Level | $97.13 | N/A |
| Average True Range (ATR) | 1.36 | 10.88 |
| MACD | -0.16 | 1.95 |
| Stochastic Oscillator | 67.68 | 100.00 |
Formed in 1997 through the merger of Grand Metropolitan and Guinness, Diageo is the largest distiller globally by sales. Diageo acquired some of the Seagram assets in 2001, which gave it brands such as Captain Morgan rum and Crown Royal Canadian whisky. Since then, mergers and acquisitions have mostly been bolt-on in nature, plugging gaps in the company's product and geographic portfolio.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.